SYMPTOMATIC THERAPY OF MULTIPLE SCLEROSIS: CORRECTION OF PSYCHOEMOTIONAL DISORDERS



Cite item

Full Text

Abstract

There were presented contemporary data, including the results of our own investigations about pathogenetic mechanisms of psychoemotional disorders, which can be found at multiple sclerosis. The results of demonstrative investigations in effectiveness of pharmacotherapy and of nonpharmacological methods of depression correction and chronic fatigue were summarized.

About the authors

Nikolaj N Spirin

Yaroslavskaya State Medical Academy of the Russian Health Ministry

Email: nnspirin@yandex.ru
Yaroslavskaya State Medical Academy of the Russian Health Ministry

Dmitry S Kasatkin

Polyclinic №5

Email: mirsil@mail.ru
Polyclinic №5

References

  1. Касаткин, Д.С. Возможные механизмы формирования синдрома усталости в клинике рассеянного склероза / Д.С. Касаткин, Н.Н. Спирин // Журн. неврол. и психиатр. им. С.С. Корсакова. Рассеянный склероз: приложение к журн. - 2006. - Вып. 3. - С. 87-92.
  2. Barak, Y. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial / Y. Barak, E. Ur, A. Achiron // J. Neuropsychiatry Clin. Neurosci. - 1999. - Vol.11. - P. 271-273.
  3. Beenakker, E.A. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production / E.A. Beenakker, T.I. Oparina, A. Hartgring et al. // Neurology. - 2001. - Vol.57. - P. 892-894.
  4. Chwastiak, L. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample / L. Chwastiak, D.M. Ehde, L.E. Gibbons et al. // Am. J. Psychiatry. - 2002. - Vol.159. - P.1862-1868.
  5. Cohen, R.A. Amantadine treatment of fatigue associated with multiple sclerosis / R.A. Cohen, M. Fisher // Arch. Neurol. - 1989. - Vol.46. - P. 676-680.
  6. Crawford, J.D. Group psychotherapy: benefits in multiple sclerosis / J.D. Crawford, G.P. McIvor // Arch. Phys. Med. Rehabil. - 1985. - Vol.66. - P. 810-813.
  7. Di Fabio, R.P. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis / R.P. Di Fabio, J. Soderberg, T. Choi et al. // Arch. Phys. Med. Rehabil. - 1998. - Vol.79. - P. 141-146.
  8. Du Boistesselin, R. Hydrotherapeutics and biophysiolo-gical de velopments. Roles of certain regulatory structures in asthenia: detection of Arcalion binding by histofluorescence // Gaz. Med. - 1988. - Vol. 95, Suppl.3. - P. 21-24.
  9. Ebers, G.C. Clinical features In: Multiple Sclerosis [Paty D.W., Ebers G.C. (eds)]. - Philadelphia: FA Davis, 1998. - P. 135-182.
  10. Feuerstein, С. Neurophysiological data concerning fatigue. Role of activator reticular formation // Entretiens de Bichat. - 1992. - Hors-serie. - P. 11-19.
  11. Finlayson, M. Pilot study of an energy conservation education program delivered by telephone conference call to people with multiple sclerosis // NeuroRehabilitation. - 2005. - Vol.20. - P. 267-277.
  12. Fisk, J.D. The Impact of Fatigue on Patients with Multiple Sclerosis / J.D. Fisk, A. Pontefract, P.G. Ritvo et al. // Can. J. Neurol. Sci. - 1994. - Vol.21. - P. 9-14.
  13. Flensner, G. The cooling-suit: case studies of its influence on fatigue among eight individuals with multiple sclerosis / G. Flensner, C. Lindencrona // J. Adv. Nurs. - 2002. - Vol.37. - P. 541-550.
  14. Freal, J.E. Symptomatic fatigue in multiple sclerosis / J.E. Freal, G.H. Kraft, J.K. Coryell // Arch. Phys. Med. Rehabil. - 1984. - Vol.65. - P.135-138.
  15. Gil, D. Antidepressants for depression in medical illness / D. Gil, S. Hatcher // Cochrane Database Syst. Rev. - 2000. - Vol.4. - CD001312.
  16. Heesen, C. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis / C. Heesen, S.M. Gold, A. Raji et al. // Psychoneuroendocrinology. - 2002. - Vol.27, №4. - P.505-517.
  17. IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicentre, randomized, double-blind, placebo-controlled trial // Neurology. - 1993. - Vol. 43. - P.655-661.
  18. Iriarte, J. Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors / J. Iriarte, M.L. Subira, P. Castro // Mult.Scler. - 2000. - Vol.6. - №2. - P.124-130.
  19. Jacobs, L.D. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis / L.D. Jacobs, D.L. Cookfair, R.A. Rudick et al. // Ann. Neurol. - 1996. - Vol.39. - P. 285-294.
  20. Kappos, L. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes / L. Kappos, C.H. Polman, M.S. Freedman et al. // Neurology. - 2006. - Vol.67, №7. - P.1242-1249.
  21. Kraft, G.H. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study / G.H. Kraft, J. Bowen // Neurology. - 2005. - Vol.65. - P.1995-1997.
  22. Krupp, L.B. Fatigue in multiple sclerosis / L.B. Krupp, L.A. Alvarez, N.G. LaRocca et al. // Arch. Neurol. - 1989. - Vol.46. - P. 841-842.
  23. Krupp, L.B. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus / L.B. Krupp, N.G. LaRocca, J. Muir-Nash et al. // Arch. Neurol. - 1989. - Vol.46. - P. 1121-1123.
  24. Krupp, L.B. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo / L.B. Krupp, P.K. Coyle, C. Doscher et al. // Neurology. - 1995. - Vol.45. - P. 1956-1961.
  25. Mathiowetz, V.G. Efficacy of an energy conservation course for persons with multiple sclerosis / V.G. Mathiowetz, K.M. Matuska, M.E. Murphy // Arch. Phys. Med. Rehabil. - 2001. - Vol.82. - P. 449-456.
  26. Mathiowetz, V.G. Randomized controlled trial of an energy conservation course for persons with multple sclerosis / V.G. Mathiowetz, M.L. Finlayson, K.M. Matuska et al. // Multiple Sclerosis. - 2005. - Vol.11. - P. 592-601.
  27. Mendoza, R.J. Unit management of depression of patients with multiple sclerosis using cognitive remediation strategies: a preliminary study / R.J. Mendoza, D.J. Pittenger, C.S. Weinstein // Neurorehabil. Neural. Repair. - 2001. - Vol.15. - P. 9-14.
  28. Metz, L.M. The effect of immunomodulatory treatment on multiple sclerosis fatigue / L.M. Metz, S.B. Patten, C.J. Archibald et al. // J. Neurol. Neurosurg. Psychiatry. - 2004. - Vol.75, 7. - P. 1045-1047.
  29. Mohr, D.C. Comparative outcomes for individual cognitive-behaviour therapy, supportive-expressive group psycho-therapy, and sertraline for the treatment of depression in multiple sclerosis / D.C. Mohr, A.C. Boudewyn, D.E. Goodkin et al. // J. Consult. Clin. Psychol. - 2001. - Vol.69. - P. 942-949.
  30. Mohr, D.C. A preliminary report on a skills-based telephone-administered peer support programme for patients with multiple sclerosis / D.C. Mohr, H. Burke, V. Beckner et al. // Mult. Scler. - 2005. - Vol.11. - P. 222-226.
  31. Mostert, S. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis / S. Mostert, J. Kesselring // Mult. Scler. - 2002. - Vol.8. - P. 161-168.
  32. Mostert, S. Effect of pulsed magnetic field therapy on the level of fatigue in patients with MS - a randomised controlled trial / S. Mostert, J. Kesselring // Mult. Scler. - 2005. - Vol.11. - P. 302-305.
  33. Oken, B.S. Randomzied controlled trial of yog and exercise in multiple sclerosis / B.S. Oken, S. Kishiyama, D. Zajdel et al. // Neurology. - 2004. - Vol.62. - P. 2058-2064.
  34. Patti, F. The impact of outpatient rehabilitation on quality of life in multiple sclerosis / F. Patti, M.R. Ciancio, E. Reggio et al. // J. Neurol. - 2002. - Vol. 249. - P. 1027-1033.
  35. Petajan, J.H. Impact of aerobic training on fitness and quality of life in multiple sclerosis / J.H. Petajan, E. Gappmaier, A.T. White et al. // Ann. Neurol. - 1996. - Vol.39. - P. 432-441.
  36. Polman, C.H. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis / C.H. Polman, F.W. Bertelsmann, R. de Waal et al. // Arch. Neurol. - 1994. - Vol.51. - P. 1136-1139.
  37. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a subcutaneously in Multiple Sclerosis) Study Group Randomised double-blind placebo-controlled study of Interferon beta-1a in relapsing-remitting multiple sclerosis // Lancet. - 1998. - Vol.352. - P.1498-1504.
  38. Rammohan, K.W. Modafinil for fatigue in MS: a rando-mized placebo-controlled double-blind study / K.W. Rammohan, D.J. Lynn // Neurology. - 2005. - Vol.65. - P. 1995-1997.
  39. Rammohan, K.W. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study / K.W. Rammohan, J.H. Rosenberg, D.J. Lynn et al. // J. Neurol. Neurosurg. Psychiatry. - 2002. - Vol.72. - P.179-183.
  40. Rossini, P.M. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine / P.M. Rossini, P. Pasqualetti, C. Pozzilli et al. // Mult. Scler. - 2001. - Vol.7. - P. 354-358.
  41. Schiffer, R.B. Antidepressant pharmacotherapy of depres-sion associated with multiple sclerosis / R.B. Schiffer, N.M. Wi-neman // Am. J. Psychiatry. - 1990. - Vol.147. - P. 1493-1497.
  42. Schwid, S.R. Fatigue in multiple sclerosis: Current understanding and future directions / S.R. Schwid, M. Covington, B.M. Segal et al. // J. Rehabil. Res. Dev. - 2002. - Vol.39. - №2. - P.211-224.
  43. Schwid, S.R. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis / S.R. Schwid, M.D. Petrie, M.P. McDermott et al. // Neurology. - 1997. - Vol.48. - P. 817-821.
  44. Schwid, S.R. A randomized controlled study of the acute and chronic effects of cooling therapy for MS / S.R. Schwid, M.D. Petrie, R. Murray et al. // Neurology. - 2003. - Vol.60. - P. 1955-1960.
  45. Sheean, G.L. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis / G.L. Sheean, N.M. Murray, J.C. Rothwell et al. // Brain. - 1998. - Vol.121. - P. 967-975.
  46. Surakka, J. Effects of aerobic and strength exercise on motor fatigue in men and women with multiple sclerosis: a randomized controlled trial / J. Surakka, A. Romberg, J. Ruutiainen et al. // Clin. Rehabil. - 2004. - Vol.18. - P. 737-748.
  47. Tomassini, V. Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial / V. Tomassini, C. Pozzilli, E. Onesti et al. // J. Neurol. Sci. - 2004. - Vol. 218. - P.103-108.
  48. Van Diemen, H.A. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study / H.A. Van Diemen, C.H. Polman, van T.M. Dongen et al. // Ann. Neurol. - 1992. - Vol.32. - P. 123-130.
  49. Weinshenker, B.G. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis / B.G. Weinshenker, M. Penman, B. Bass et al. // Neurology. - 1992. - Vol.42. - P. 1468-1471.
  50. White, A.T. Effect of precooling on physical performance in multiple sclerosis / A.T. White, T.E. Wilson, S.L. Davis et al. // Mult. Scler. - 2000. - Vol.6. - P.176-180.
  51. Wingerchuk, D.M. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis / D.M. Win-gerchuk, E.E. Benarroch, P.C. O'Brien. // Neurology. - 2005. - Vol.64, №7. - P. 1267-1269.
  52. Zephir, H. Multiple sclerosis and depression: influence of interferon beta therapy / H. Zephir, J. De Seze, T. Stojkovic et al. // Mult. Scler. - 2003. - Vol. 9. - P. 284-288.
  53. Ziemssen, T. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis / T. Ziemssen, J. Hoffman, R. Apfel et al. // Health Qual. Life Outcomes. - 2008. - Vol.6. - P. 67.
  54. Ziemssen, T. Multiple sclerosis beyond EDSS: depression and fatigue // J. Neurol. Sci. - 2009. - Vol.277. - Suppl.1. - P. 37-41.
  55. Zifko, U.A. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study / U.A. Zifko, M. Rupp, S. Schwarz et al. // J. Neurol. - 2002. - Vol.249. - P. 983-987.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Spirin N.N., Kasatkin D.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies